A red blood cell distribution width (RDW) test is an important part of a complete blood count (CBC) test. It measures the range of red blood cell sizes in the body. A high RDW result can indicate anemia, inflammation, or other health conditions. In this article, we will discuss the meaning of a high RDW result, and its potential implications.
RDW is a measure of the range of red blood cell sizes in the body. It is usually expressed as a percentage. The size of red blood cells can vary from person to person, but a high RDW result indicates that the size of the red blood cells is unusually wide.
A high RDW result can indicate a number of possible health conditions. It can be a sign of anemia, which is a condition in which the body does not have enough healthy red blood cells. It can also be a sign of inflammation, which is a response of the body to infection or injury. In some cases, it can be a sign of a vitamin B12 or folate deficiency.
If a high RDW result is found on a CBC test, further tests may be needed to diagnose the cause. These tests may include a ferritin test to check for anemia, a C-reactive protein test to check for inflammation, and a vitamin B12 and folate test to check for deficiencies.
The treatment for a high RDW result will depend on the underlying cause. If the cause is anemia, iron supplements may be prescribed to increase the number of healthy red blood cells in the body. If the cause is inflammation, anti-inflammatory medication may be prescribed. If the cause is a vitamin B12 or folate deficiency, supplements may be prescribed.
A high RDW result can be a sign of several different health conditions. It is important to discuss any abnormal results with a doctor, who can order further tests to diagnose the cause. Depending on the underlying cause, treatment may involve iron supplements, anti-inflammatory medication, or vitamin B12 or folate supplements.
1.
A study outlines the need for policies that enhance cancer patients' autonomy and information.
2.
New CAR T-Cell Therapy Approved for Leukemia
3.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
4.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
5.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
1.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
2.
Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases
3.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
4.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
5.
Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
2.
Thromboprophylaxis In Medical Settings
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation